Xilio Therapeutics (XLO) risk factors, FY2024 10-K

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

1. 01Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to product candidates or our technology
2. 02If in the future we fail to comply with the continued listing requirements of Nasdaq, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted
3. 03We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future
4. 04We have no products approved for commercial sale and have not generated any revenue from product sales. We may never generate any revenue from product sales or become profitable and, if we achieve profitability, we may not be able to sustain it
5. 05Our limited operating history may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability
6. 06Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited

Risks Related to the Discovery and Development of Our Product Candidates

1. 07Our business is highly dependent on the success of our current product candidates, which are in the early stages of development and will require significant additional preclinical and clinical development before we can seek regulatory approval for and commercially launch a product
2. 08Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business
3. 09Preclinical studies and clinical trials are expensive, time-consuming and difficult to design and implement, and involve uncertain outcomes. Furthermore, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials
4. 10We may encounter substantial delays in the commencement or completion, or termination or suspension, of our clinical trials, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects
5. 11If we experience delays or difficulties in the enrollment of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected
6. 12Our product candidates may cause undesirable or unexpectedly severe side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any
7. 13Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
8. 14We expect to develop certain of our product candidates in combination with third-party drugs and we will have limited or no control over the safety, supply, regulatory status or regulatory approval of such third-party drugs
9. 15We may not be successful in our efforts to use our platform technology to enable the development of a pipeline of tumor-activated product candidates
10. 16We may not be successful in our efforts to identify or discover additional product candidates
11. 17Our approach to the discovery and development of product candidates based on our technological approaches is unproven, and we do not know whether we will be able to develop any products of commercial value
12. 18We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
13. 19We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or following commercial sale, and any product liability insurance we may obtain may not cover all damages from such claims

Risks Relating to Manufacturing and Supply

1. 20Manufacturing biologics is complex, and we may experience manufacturing problems that result in delays in our development or commercialization programs
2. 21cause reputational damage. In the event that raw materials required in our manufacturing process need to be derived from biologic sources, they may be difficult to procure and may be subject to contamination or recall
3. 22Any of these events could lead to clinical trial delays or failure to obtain regulatory approval or impact our ability to successfully commercialize future products. Some of these events could be the basis for FDA action, including injunction, recall, seizure, import alert, or total or partial suspension of production
4. 23Certain of our research and development and manufacturing activities take place in China through WuXi Biologics. A significant disruption in our ability to rely on WuXi Biologics could materially adversely affect our business, financial condition and results of operations
5. 24If we or any CDMOs and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business

Risks Related to our Dependence on Third Parties

1. 25We expect to rely on third parties to conduct, supervise and monitor IND-enabling studies and clinical trials, and if these third parties perform in an unsatisfactory manner, it may harm our business, reputation and results of operations
2. 26If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans
3. 27Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators

Risks Related to Commercialization

1. 28We have never commercialized a product candidate and we may lack the necessary expertise, personnel and resources to successfully commercialize any products that receive regulatory approval, either on our own or together with collaborators
2. 29We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
3. 30candidates. Competition may further increase with advances in the commercial applicability of technologies and greater availability of capital for investment in these industries
4. 31If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of any of our product candidates may be delayed, and our business could be harmed
5. 32If approved, our product candidates that are licensed and regulated as biological products, or biologics, may face competition from biosimilars approved through an abbreviated regulatory pathway
6. 33The sizes of the potential markets for our product candidates are difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates
7. 34The successful commercialization of our product candidates will depend in part on the extent to which we obtain and maintain favorable insurance coverage, adequate reimbursement levels and cost-effective pricing policies with third-party payors
8. 35Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community necessary for commercial success

Risks Related to Our Intellectual Property

1. 36Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
2. 37Issued patents covering our product candidates or technology could be found invalid or unenforceable if challenged in court or the USPTO
3. 38Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
4. 39We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world
5. 40Biotechnology and pharmaceutical companies generally, and we in particular, compete in a crowded competitive space characterized by rapidly evolving technologies and aggressive development of intellectual property
6. 41Our proprietary position depends upon patents that are manufacturing, formulation or method-of-use patents, which may not prevent a competitor or other third party from designing around or using the same product candidate for another use
7. 42If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
8. 43Third-party claims of intellectual property infringement or violations may prevent or delay our discovery and development efforts
9. 44We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses
10. 45intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer
11. 46We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful
12. 47We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
13. 48We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors
14. 49If we do not obtain patent term extension for any of our current or future product candidates, our business may be materially harmed
15. 50If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected
16. 51Numerous factors may limit any potential competitive advantage provided by our intellectual property rights

Risks Related to Regulatory Approval and Other Legal Compliance Matters

1. 52Accordingly, any delay in obtaining or failure to obtain required approvals could negatively affect our ability or that of any future collaborators to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price
2. 53Disruptions in the FDA and other government agencies for any reason could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business
3. 54government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable
4. 55We may not be able to obtain orphan drug designation or orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing products
5. 56the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition
6. 57Any product candidate for which we obtain marketing approval is subject to ongoing regulation and could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements, when and if any of our product candidates are approved
7. 58unlawful promotion of a new intended use for the approved product. We will need to carefully navigate the FDA’s various regulations, guidance and policies, along with recently enacted legislation, to ensure compliance with restrictions governing promotion of our products
8. 59Accelerated approval by the FDA, even if granted for any of our current or future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval
9. 60Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for any of our candidate products that do receive marketing approval
10. 61Current and future legislative efforts may limit the prices for our products, if and when they are licensed for marketing, and that could materially impact our ability to generate revenues
11. 62implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA’s standards for accelerated approval
12. 63physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year
13. 64be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future
14. 65We are subject to U.S. and certain foreign export control, import, sanctions, anti-corruption, and anti-money laundering laws and regulations with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business
15. 66Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results
16. 67If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business
17. 68Our employees, independent contractors, CROs, consultants, commercial partners, vendors and principal investigators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements

Risks Related to Our Business Operations, Employee Matters and Managing Growth

1. 69Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel
2. 70A variety of risks associated with marketing our product candidates internationally, if approved, could materially adversely affect our business
3. 71We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management
4. 72Our operations or those of the third parties upon whom we depend might be affected by the occurrence of a catastrophic event, such as a terrorist attack, war or other armed conflict, geopolitical tensions or trade wars, pandemic or natural disaster

Risks Related to Ownership of Our Common Stock and Our Status as a Public Company

1. 73Our common stock may be subject to a low trading volume and volatile market price related or unrelated to our operations and purchasers of our common stock could have difficulty selling their shares or could suffer a decline in value
2. 74If securities or industry analysts do not publish research or reports about our company, or if they issue unfavorable or inaccurate research regarding our business, or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline
3. 75Our principal stockholders and management own a significant percentage of our common stock and exert significant control over matters subject to stockholder approval
4. 76other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that our stockholders may feel are in their best interest
5. 77We have broad discretion regarding use of our cash and cash equivalents, and we may not use them effectively
6. 78We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
7. 79We are an “emerging growth company” and a “smaller reporting company” and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
8. 80We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile
9. 81We have incurred and will continue to incur substantial costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices
10. 82Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
11. 83Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition
12. 84development expenditures currently and requires corporations to capitalize and amortize them over five years or fifteen years (for expenditures attributable to foreign research)
13. 85Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management
14. 86person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner